Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors

GlobeNewswire August 25, 2022

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022

Vaxart Appoints W. Mark Watson to its Board of Directors

GlobeNewswire August 8, 2022

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

GlobeNewswire August 5, 2022

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

GlobeNewswire July 28, 2022

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

GlobeNewswire July 27, 2022

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

GlobeNewswire July 20, 2022

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

GlobeNewswire July 14, 2022

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

GlobeNewswire July 1, 2022

Vaxart Announces Agreement with hVIVO to Develop World's First Human Omicron Challenge Model

GlobeNewswire June 30, 2022

Vaxart to Host Investor Q&A Webcast

GlobeNewswire June 16, 2022

Vaxart Announces Adjournment of Annual Meeting of Stockholders

GlobeNewswire June 8, 2022

New Preclinical Data Demonstrate Two of Vaxart's COVID-19 Vaccine Candidates Protect Against Omicron

GlobeNewswire June 3, 2022

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

GlobeNewswire June 2, 2022

Vaxart to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire June 2, 2022

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

GlobeNewswire May 19, 2022

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 9, 2022

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

GlobeNewswire April 14, 2022

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 24, 2022

Vaxart's S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

GlobeNewswire February 24, 2022